These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29568632)

  • 1. Delays in switching patients onto second-line antiretroviral treatment at a public hospital in eThekwini, KwaZulu-Natal.
    Narainsamy D; Mahomed S
    South Afr J HIV Med; 2017; 18(1):696. PubMed ID: 29568632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of switch to paediatric second-line antiretroviral therapy after first-line failure in Cameroon.
    Njom-Nlend AE; Efouba N; Brunelle Sandie A; Fokam J
    Trop Med Int Health; 2021 Aug; 26(8):927-935. PubMed ID: 33905593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.
    Ssempijja V; Nakigozi G; Chang L; Gray R; Wawer M; Ndyanabo A; Kasule J; Serwadda D; Castelnuovo B; Hoog AV; Reynolds SJ
    BMC Infect Dis; 2017 Aug; 17(1):582. PubMed ID: 28830382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome.
    Johnston V; Fielding K; Charalambous S; Mampho M; Churchyard G; Phillips A; Grant AD
    PLoS One; 2012; 7(5):e36997. PubMed ID: 22666338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program.
    Johnston V; Fielding KL; Charalambous S; Churchyard G; Phillips A; Grant AD
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):370-80. PubMed ID: 22820803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.
    Rohr JK; Ive P; Horsburgh CR; Berhanu R; Shearer K; Maskew M; Long L; Sanne I; Bassett J; Ebrahim O; Fox MP
    PLoS One; 2016; 11(8):e0161469. PubMed ID: 27548695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second-line switches in Swaziland.
    Etoori D; Ciglenecki I; Ndlangamandla M; Edwards CG; Jobanputra K; Pasipamire M; Maphalala G; Yang C; Zabsonre I; Kabore SM; Goiri J; Teck R; Kerschberger B
    J Int AIDS Soc; 2018 Oct; 21(10):e25194. PubMed ID: 30350392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.
    ; Keiser O; Tweya H; Boulle A; Braitstein P; Schecter M; Brinkhof MW; Dabis F; Tuboi S; Sprinz E; Pujades-Rodriguez M; Calmy A; Kumarasamy N; Nash D; Jahn A; MacPhail P; Lüthy R; Wood R; Egger M
    AIDS; 2009 Sep; 23(14):1867-74. PubMed ID: 19531928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study.
    Hermans LE; Carmona S; Nijhuis M; Tempelman HA; Richman DD; Moorhouse M; Grobbee DE; Venter WDF; Wensing AMJ
    PLoS Med; 2020 Feb; 17(2):e1003037. PubMed ID: 32097428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes after first-line HIV treatment failure in South Africa: the next cascade of care.
    Iwuji CC; Shahmanesh M; Koole O; Herbst K; Pillay D; Siedner MJ; Baisley K;
    HIV Med; 2020 Aug; 21(7):457-462. PubMed ID: 32495515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.
    Johnston V; Cohen K; Wiesner L; Morris L; Ledwaba J; Fielding KL; Charalambous S; Churchyard G; Phillips A; Grant AD
    J Infect Dis; 2014 Mar; 209(5):711-20. PubMed ID: 23943851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa.
    Evans D; Hirasen K; Berhanu R; Malete G; Ive P; Spencer D; Badal-Faesen S; Sanne IM; Fox MP
    AIDS Res Ther; 2018 Apr; 15(1):10. PubMed ID: 29636106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India.
    Khan S; Das M; Andries A; Deshpande A; Mansoor H; Saranchuk P; Isaakidis P
    Glob Health Action; 2014; 7():24861. PubMed ID: 25084835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.
    Shroufi A; Van Cutsem G; Cambiano V; Bansi-Matharu L; Duncan K; Murphy RA; Maman D; Phillips A
    AIDS; 2019 Aug; 33(10):1635-1644. PubMed ID: 31305331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.
    Fox MP; Cutsem GV; Giddy J; Maskew M; Keiser O; Prozesky H; Wood R; Hernán MA; Sterne JA; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):428-37. PubMed ID: 22433846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
    Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
    Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa.
    Bell Gorrod H; Court R; Schomaker M; Maartens G; Murphy RA
    J Acquir Immune Defic Syndr; 2020 May; 84(1):107-113. PubMed ID: 32032304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.
    Amstutz A; Nsakala BL; Vanobberghen F; Muhairwe J; Glass TR; Namane T; Mpholo T; Battegay M; Klimkait T; Labhardt ND
    PLoS Med; 2020 Sep; 17(9):e1003325. PubMed ID: 32936795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring barriers to switching "on time" to second-line antiretroviral therapy among nurses in primary health care facilities, Ekurhuleni Health District, South Africa.
    Tenza IS; Njuguna C; Sodo PP; Ruch A; Francis JM; Omole OB; Cooke R; Agbo S; Baldwin-Ragaven L
    PLoS One; 2023; 18(4):e0284996. PubMed ID: 37099552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.